Free Trial

Brokerages Set Natera, Inc. (NASDAQ:NTRA) Price Target at $178.12

Natera logo with Medical background
Remove Ads

Shares of Natera, Inc. (NASDAQ:NTRA - Get Free Report) have earned an average rating of "Buy" from the sixteen analysts that are presently covering the stock, MarketBeat reports. Sixteen investment analysts have rated the stock with a buy recommendation. The average 12-month price target among brokers that have covered the stock in the last year is $178.12.

NTRA has been the topic of several recent analyst reports. Robert W. Baird boosted their price target on Natera from $183.00 to $188.00 and gave the stock an "outperform" rating in a research report on Friday, February 28th. Piper Sandler upped their price target on shares of Natera from $200.00 to $205.00 and gave the stock an "overweight" rating in a research report on Tuesday, March 4th. The Goldman Sachs Group increased their price target on shares of Natera from $160.00 to $190.00 and gave the company a "buy" rating in a research note on Tuesday, January 28th. Guggenheim boosted their target price on Natera from $170.00 to $200.00 and gave the stock a "buy" rating in a report on Friday, January 17th. Finally, BTIG Research reaffirmed a "buy" rating on shares of Natera in a report on Friday, February 28th.

Check Out Our Latest Stock Analysis on Natera

Natera Stock Up 0.7 %

NTRA traded up $1.03 during trading on Friday, reaching $149.25. The company had a trading volume of 1,325,380 shares, compared to its average volume of 1,342,578. The business's fifty day moving average price is $163.70 and its 200 day moving average price is $148.83. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.23. Natera has a 12 month low of $83.13 and a 12 month high of $183.00. The company has a market cap of $20.18 billion, a P/E ratio of -84.80 and a beta of 1.80.

Remove Ads

Natera (NASDAQ:NTRA - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The medical research company reported ($0.41) EPS for the quarter, beating the consensus estimate of ($0.42) by $0.01. The business had revenue of $476.10 million for the quarter, compared to analysts' expectations of $447.91 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. Equities analysts anticipate that Natera will post -1.49 EPS for the current year.

Insider Transactions at Natera

In related news, Director Gail Boxer Marcus sold 4,000 shares of Natera stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $147.69, for a total transaction of $590,760.00. Following the sale, the director now directly owns 9,704 shares of the company's stock, valued at approximately $1,433,183.76. The trade was a 29.19 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Steven Leonard Chapman sold 87,272 shares of the stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $143.40, for a total transaction of $12,514,804.80. Following the completion of the transaction, the chief executive officer now directly owns 203,354 shares of the company's stock, valued at approximately $29,160,963.60. The trade was a 30.03 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 298,946 shares of company stock valued at $47,803,462. Company insiders own 7.60% of the company's stock.

Hedge Funds Weigh In On Natera

Several large investors have recently bought and sold shares of the company. Assetmark Inc. boosted its position in Natera by 2.1% during the 3rd quarter. Assetmark Inc. now owns 7,353 shares of the medical research company's stock worth $933,000 after buying an additional 150 shares during the period. Covestor Ltd lifted its holdings in shares of Natera by 34.3% during the third quarter. Covestor Ltd now owns 372 shares of the medical research company's stock worth $47,000 after purchasing an additional 95 shares during the period. Apollon Wealth Management LLC acquired a new position in shares of Natera during the third quarter worth $270,000. Sumitomo Mitsui Trust Group Inc. grew its stake in shares of Natera by 29.6% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 671,382 shares of the medical research company's stock worth $85,232,000 after purchasing an additional 153,441 shares during the last quarter. Finally, Victory Capital Management Inc. increased its holdings in Natera by 4.2% in the third quarter. Victory Capital Management Inc. now owns 315,543 shares of the medical research company's stock valued at $40,058,000 after purchasing an additional 12,815 shares during the period. 99.90% of the stock is currently owned by institutional investors.

About Natera

(Get Free Report

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

Read More

Analyst Recommendations for Natera (NASDAQ:NTRA)

Should You Invest $1,000 in Natera Right Now?

Before you consider Natera, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Natera wasn't on the list.

While Natera currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.

Get This Free Report
Like this article? Share it with a colleague.
Remove Ads

Featured Articles and Offers

7 Inflation-Proof Stocks to Protect Your Portfolio

7 Inflation-Proof Stocks to Protect Your Portfolio

Inflation is sticking around—is your portfolio ready? In this video, we break down 7 stocks that could help shield your investments from inflation’s impact.

Related Videos

7 Large-Cap Stocks Headed for Strong, Steady Gains in 2025

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines

Remove Ads